Acquisitions, Assets and Liabilities Held for Sale, Research and Development and Collaborative Arrangements, Equity-Method Investments and Cost-Method Investment (Tables)

9 Months Ended

Oct. 02, 2016

Business Combinations, Discontinued Operations And Disposal Groups, Collaborative Arrangements And Equity Method Investments [Abstract]

Schedule of Amounts Recognized for Assets Acquired and Liabilities Assumed

The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date, as well as adjustments made in the first nine months of 2016 to the amounts initially recorded in 2015 (measurement period adjustments) with a corresponding change to goodwill. The measurement period adjustments did not have a material impact on our earnings in any period. The final allocation of the consideration transferred to the assets acquired and the liabilities assumed has been completed.

(MILLIONS OF DOLLARS)	Amounts Recognized as of Acquisition Date (as previously reported as of December 31, 2015)			Measurement Period Adjustments(a)			Amounts Recognized as of Acquisition Date (as adjusted) Final
Working capital, excluding inventories	$	274		$	68		$	342
Inventories	1,924			(23		)	1,901
PP&E	2,410			(57		)	2,352
Identifiable intangible assets, excluding IPR&D	8,270			20			8,290
IPR&D	995			35			1,030
Other noncurrent assets	408			(46		)	362
Long-term debt	(1,928		)	—			(1,928		)
Benefit obligations	(117		)	—			(117		)
Net income tax accounts	(3,394		)	14			(3,380		)
Other noncurrent liabilities	(39		)	(23		)	(61		)
Total identifiable net assets	8,803			(12		)	8,791
Goodwill	7,284			12			7,295
Net assets acquired/total consideration transferred	$	16,087		$	—		$	16,087

^(a)  The changes in the estimated fair values are primarily to better reflect market participant assumptions about facts and circumstances existing as of the acquisition date. The measurement period adjustments did not result from intervening events subsequent to the acquisition date.

Summary of Pro Forma Information

The following table provides supplemental pro forma information as if the acquisition of Hospira had occurred on January 1, 2014:
	Unaudited Supplemental Pro Forma Consolidated Results
	Three Months Ended		Nine Months Ended
(MILLIONS OF DOLLARS, EXCEPT PER SHARE DATA)	September 27, 2015		September 27, 2015
Revenues	$	12,957	$	38,034
Net income attributable to Pfizer Inc. common shareholders	2,513		7,577
Diluted EPS attributable to Pfizer Inc. common shareholders	0.40		1.21

Summary of Assets and Liabilities Held for Sale

The amounts associated with HIS, as well as other assets classified as held for sale as of October 2, 2016 and December 31, 2015, consisted of the following:

(MILLIONS OF DOLLARS)	October 2, 2016			December 31, 2015
Assets Held for Sale
Inventories	$	369		$	—
Property, plant and equipment	441			—
Identifiable intangible assets	1,322			—
Goodwill	243			—
Other assets	60			—
Less: adjustment to HIS assets for net realizable value(a)	(1,394		)	—
Total HIS assets held for sale	1,042			—
Other assets held for sale(b)	77			9
Assets held for sale	$	1,119		$	9
Liabilities Held for Sale
Accrued compensation and related items	$	42		$	—
Other liabilities	68			—
Total HIS liabilities held for sale	$	110		$	—

^(a)  For the quarter ending October 2, 2016, we recorded an adjustment to HIS assets for net realizable value of $1,394 million plus estimated costs to sell of $28 million for a total impairment on HIS net assets of $1,422 million.

^(b)  Other assets held for sale consist primarily of property, plant and equipment and other assets.